SALT LAKE CITY, UT--(Marketwire - April 28, 2009) - Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present an overview of the Company at the Bank of America and Merrill Lynch 2009 Health Care Conference, at 2:00 p.m. EDT on May 12, at The Palace Hotel in New York, NY. Gregory C. Critchfield, M.D., President of Myriad Genetic Laboratories, Inc., will present an overview of the Company at The Eighth Annual JMP Securities Research Conference, at 10:30 a.m. PDT (1:30 p.m. EDT) on May 18, 2009, at The Ritz-Carlton in San Francisco, CA.
The Bank of America and Merrill Lynch presentation will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's Web site at www.myriad.com.
About Myriad Genetics
Myriad Genetics, Inc. is a leading healthcare company focused on the development and marketing of novel molecular diagnostic and therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, Azixa and Vivecon are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G
This press release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements relating to the scheduled presentation of an overview of the
Company at the Bank of America and Merrill Lynch 2009 Health Care
Conference on May 12, 2009, and The Eighth Annual JMP Securities Research
Conference on May 18, 2009. These "forward-looking statements" are based on
management's current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by
forward-looking statements. These risks and uncertainties include, but are
not limited to: the risk that we may be unable to further identify,
develop and achieve commercial success for new products and technologies;
the risk that we may be unable to discover drugs that are safer and more
efficacious than our competitors; the risk that we may be unable to develop
manufacturing capability for approved products; the risk that sales of our
existing molecular diagnostic products may decline or not continue to
increase at historical rates; the risk that we may be unable to develop
additional molecular diagnostic products that help assess which patients
are subject to greater risk of developing diseases and who would therefore
benefit from new preventive therapies; the possibility of delays in the
research and development necessary to select drug development candidates
and delays in clinical trials; the risk that clinical trials may not result
in marketable products; the risk that we may be unable to successfully
finance and secure regulatory approval of and market our drug candidates,
or that clinical trials will not be completed on the timelines we have
estimated; uncertainties about our ability to obtain new corporate
collaborations and acquire new technologies on satisfactory terms, if at
all; the development of competing products and services; the risk that we
may be unable to protect our proprietary technologies; the risk of
patent-infringement claims; risks of new, changing and competitive
technologies and regulations in the United States and internationally; and
other factors discussed under the heading "Risk Factors" contained in Item
1A in our Annual Report on Form 10-K for the year ended June 30, 2008,
which has been filed with the Securities and Exchange Commission, as well
as any updates to those risk factors filed from time to time in our
Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All
information in this press release is as of the date of the release, and
Myriad undertakes no duty to update this information unless required by
law.
